Attached files

file filename
EX-10.20 - EX-10.20 - ZIOPHARM ONCOLOGY INCd861766dex1020.htm
EX-32.1 - EX-32.1 - ZIOPHARM ONCOLOGY INCd861766dex321.htm
EX-31.2 - EX-31.2 - ZIOPHARM ONCOLOGY INCd861766dex312.htm
EX-31.1 - EX-31.1 - ZIOPHARM ONCOLOGY INCd861766dex311.htm
EX-23.1 - EX-23.1 - ZIOPHARM ONCOLOGY INCd861766dex231.htm
EX-21.1 - EX-21.1 - ZIOPHARM ONCOLOGY INCd861766dex211.htm
EX-10.23 - EX-10.23 - ZIOPHARM ONCOLOGY INCd861766dex1023.htm
EX-10.21 - EX-10.21 - ZIOPHARM ONCOLOGY INCd861766dex1021.htm
EX-4.8 - EX-4.8 - ZIOPHARM ONCOLOGY INCd861766dex48.htm
EX-4.7 - EX-4.7 - ZIOPHARM ONCOLOGY INCd861766dex47.htm
10-K - 10-K - ZIOPHARM ONCOLOGY INCd861766d10k.htm

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of ZIOPHARM Oncology, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2019, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Satyavrat Shukla, Principal Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

  (1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

  (2)

The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

/s/ Satyavrat Shukla    

Satyavrat Shukla

Executive Vice President and Chief Financial Officer

(Principal Financial Officer)
March 2, 2020